

# UCLA

## UCLA Previously Published Works

### Title

Hepatocellular carcinoma surveillance: current practice and future directions

### Permalink

<https://escholarship.org/uc/item/9323x3dh>

### Authors

Ahn, Joseph C

Lee, Yi-Te

Agopian, Vatche G

et al.

### Publication Date

2022

### DOI

10.20517/2394-5079.2021.131

### Copyright Information

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed



Published in final edited form as:

*Hepatology Res.* 2022 ; 8: . doi:10.20517/2394-5079.2021.131.

## Hepatocellular carcinoma surveillance: current practice and future directions

Joseph C. Ahn<sup>1</sup>, Yi-Te Lee<sup>2,3</sup>, Vatche G. Agopian<sup>4,5</sup>, Yazhen Zhu<sup>2,3</sup>, Sungyong You<sup>6,7</sup>, Hsian-Rong Tseng<sup>2,3</sup>, Ju Dong Yang<sup>6,8,9</sup>

<sup>1</sup>Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN 55905, USA.

<sup>2</sup>California NanoSystems Institute, Crump Institute for Molecular Imaging, University of California, Los Angeles, CA 90095, USA.

<sup>3</sup>Department of Molecular and Medical Pharmacology, University of California, Los Angeles, CA 90095, USA.

<sup>4</sup>Department of Surgery, University of California, Los Angeles, CA 90095, USA.

<sup>5</sup>Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA 90048, USA.

<sup>6</sup>Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

<sup>7</sup>Departments of Surgery, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

<sup>8</sup>Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

<sup>9</sup>Comprehensive Transplant Center Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

### Abstract

Hepatocellular carcinoma (HCC) is among the leading causes of cancer incidence and mortality worldwide. Surveillance of individuals with cirrhosis or other conditions that confer a high risk

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

**Correspondence to:** Dr. Ju Dong Yang, Karsh Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, 8900 Beverly Blvd, Los Angeles, CA 90048, USA. [judong.yang@cshs.org](mailto:judong.yang@cshs.org).

Authors' contributions

Devised the project and the main conceptual ideas for the review: Yang JD

Conducted the literature search and identified relevant studies to be included in the review: Ahn JC

Provided technical expertise on novel biomarkers of HCC: Lee YT, Agopian VG, Zhu Y, You S, Tseng HR

Drafted the manuscript with the help of Lee YT: Ahn JC

Revised the manuscript critically for important intellectual content: Yang JD, Tseng HR

All authors approved the final version to be published.

#### DECLARATIONS

Availability of data and materials

Not applicable.

Ethical approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

of HCC development is essential for early detection and improved overall survival. Biannual ultrasonography with or without alpha-fetoprotein is widely recommended as the standard method for HCC surveillance, but it has limited sensitivity in early disease and may be inadequate in certain individuals. This review article will provide a comprehensive overview of the current landscape of HCC surveillance, including the rationale and indications for HCC surveillance, standard methods for HCC surveillance, and their strengths/limitations. Alternative surveillance methods such as the role of cross-sectional imaging, emerging circulating biomarkers, as well as the problem of under-utilization of HCC surveillance and surveillance-related harms will also be discussed in this review.

### Keywords

Hepatocellular carcinoma; surveillance; cirrhosis; hepatitis B virus; alpha-fetoprotein; liquid biopsy; under-utilization

## INTRODUCTION

Liver cancer is among the leading causes of global cancer incidence and is the second-most common cause of cancer mortality<sup>[1,2]</sup>. Hepatocellular carcinoma (HCC) is the most dominant form of primary cancer, accounting for roughly 80% of all cases of liver cancer, and occurs in patients with chronic liver diseases of various causes<sup>[3]</sup>. The burden of HCC has historically been high in Asia, with China accounting for over 51% of the global liver cancer burden<sup>[4]</sup>. While a recent analysis has projected a decrease in the incidence and mortality rates of liver cancer in China through 2030, it also emphasized that the overall disease burden would still be serious, especially in rural and western areas due to the persistently high prevalence of HBV and HCV, as well as aflatoxin and alcohol-related liver diseases<sup>[5]</sup>. In the Western world, the HCC incidence rates remain elevated due to the rising prevalence of cirrhosis due to non-alcoholic steatohepatitis (NASH)<sup>[6]</sup> and alcohol-related liver diseases<sup>[7]</sup>. While there have been significant advances in the treatment of HCC, the overall prognosis in patients with large tumor burden, vascular invasion, or extrahepatic spread continues to remain extremely poor<sup>[8,9]</sup>. Therefore, surveillance of high-risk patients is critical for the detection of HCC at earlier stages where curative options are still available. This review article will provide a comprehensive overview of the indications and rationale for HCC surveillance, currently available surveillance methods and their utilization, effectiveness, and limitations, as well as novel surveillance tools which are emerging as alternatives.

## RATIONALE FOR HCC SURVEILLANCE

The stage at cancer diagnosis is the most important factor determining overall survival in patients with HCC<sup>[10]</sup>. Patients with small, localized tumors may receive curative treatments such as resection, ablation, or liver transplantation, and their long-term survival can be excellent<sup>[11]</sup>. On the other hand, patients with large, multifocal tumors, macrovascular invasion, or extrahepatic metastasis can only receive palliative treatments and have significantly poorer survival despite the advent of newer locoregional and systemic treatment options<sup>[12]</sup>. Therefore, the goal of a surveillance program for HCC is to diagnose tumors at

early stages in high-risk individuals so that they can receive curative treatments and achieve improved long-term survival, translating into a decrease in liver cancer mortality<sup>[9]</sup>.

In principle, a randomized controlled trial (RCT) is the best study design to evaluate the effectiveness of medical intervention. However, there has been a paucity of properly conducted, universally generalizable RCTs on the benefits of HCC surveillance. Only two RCTs have been reported, both of which were single-center studies from China in patients with chronic viral hepatitis<sup>[13,14]</sup>. While one of the studies showed a significantly reduced mortality rate in the screening group compared to the control group (HR = 0.63, 95% CI: 0.41–0.98)<sup>[14]</sup>, the other study did not show a difference in mortality (HR = 0.83, 95% CI: 0.68–1.03)<sup>[13]</sup>. In addition, neither study offered their patients the option of choosing nonrandomized screening, and neither study provided information on individual informed consent or contemporary local clinical practice, creating an ethical concern. In 2011, Poustchi *et al.*<sup>[15]</sup> tested the feasibility of conducting an RCT of HCC surveillance in patients with cirrhosis, and concluded that an RCT of HCC surveillance is not feasible, as most patients decline randomization and prefer to receive surveillance when provided with informed consent.

Despite the absence of large-scale, generalizable RCT data, there is a clear association between receipt of HCC surveillance and improved outcomes. In general, surveillance is considered beneficial to an individual if it provides an increase in life expectancy of around 100 days<sup>[16]</sup>, and cost-effective if surveillance costs < \$50,000 per year of life gained<sup>[17]</sup>. A meta-analysis of 47 studies with 15,158 patients demonstrated that HCC surveillance was associated with significantly higher rates of early detection [odds ratio (OR) = 2.08,  $P < 0.01$ ], curative treatments (OR = 2.24,  $P < 0.01$ ), and prolonged survival (OR = 1.90,  $P < 0.01$ ) even after adjusting for lead-time bias<sup>[18]</sup>. Lin *et al.*<sup>[19]</sup> evaluated the cost-effectiveness of HCC surveillance using a Markov model and determined that ultrasound and alpha-fetoprotein (AFP) was effective with a cost-effectiveness ratio < \$50,000 per quality-adjusted life-year. A multistate Markov model simulating a cohort of 50-year-old patients with cirrhosis demonstrated that HCC surveillance decreases all-cause and tumor-specific mortality in patients with compensated cirrhosis regardless of the availability of liver transplantation<sup>[20]</sup>.

## INDICATIONS FOR HCC SURVEILLANCE

Table 1 provides a summary of the latest HCC surveillance recommendations from the American Association for the Study of Liver Diseases (AASLD)<sup>[21]</sup>, European Association for the Study of the Liver (EASL)<sup>[22]</sup>, and Asian Pacific Association for the Study of the Liver (APASL)<sup>[23]</sup>. Patients with cirrhosis have HCC incident rates ranging from 1% to 8% annually and comprise more than 80% of newly diagnosed HCC cases<sup>[21]</sup>. Therefore, all major guidelines recommend HCC surveillance in patients with cirrhosis, except in patients with transplant-ineligible Child-Pugh class C cirrhosis, as HCC surveillance will not provide survival benefit for them due to the competing risk of death from liver failure<sup>[21–23]</sup>.

Another high-risk group includes patients with chronic HBV (CHB) infection. In addition to causing chronic inflammation and fibrosis in the liver, HBV integrates its genome into hepatocyte DNA and induces genetic damage, and can promote carcinogenesis even in the

absence of cirrhosis<sup>[24]</sup>. While HCC incidence in CHB patients without cirrhosis is generally lower than in patients with cirrhosis, demographic factors such as age, sex, race/ethnicity, and family history of HCC have been associated with a higher risk of developing HCC. AASLD and APASL recommend HCC surveillance in CHB patients who meet the following criteria: Asian men over 40 years of age; Asian women over 50 years of age; African or African-American; family history of HCC<sup>[21,23]</sup>. EASL guideline utilizes a classification system called PAGE-B (platelet, age, gender, hepatitis B) to define high-risk patients with CHB who would benefit from surveillance<sup>[22,25]</sup>.

While chronic HCV (CHC) infection usually does not cause HCC in the absence of cirrhosis, studies have found that non-cirrhotic CHC patients with high scores in noninvasive markers of fibrosis such as APRI (> 2.0) and FIB-4 (> 4.5) can develop HCC<sup>[26]</sup>. Therefore, the most recent Chinese clinical guidelines for the management of HCC recommend screening all non-cirrhotic patients with CHB as well as chronic HCV infections<sup>[27]</sup>.

The burden of NAFLD-related HCC is rapidly increasing in the United States. While NAFLD patients without cirrhosis have less than 1% annual risk of developing HCC, the high prevalence of NAFLD may still lead to a substantial number of HCC cases among NAFLD patients without cirrhosis. As a result, the most recent practice guidance from the American Gastroenterological Association recommends considering HCC surveillance in patients with NAFLD whose noninvasive markers suggest evidence of advanced liver fibrosis<sup>[28]</sup>.

## UNDER-UTILIZATION OF HCC SURVEILLANCE

The effectiveness of HCC surveillance at improving outcomes in high-risk patients relies not only on the accuracy of surveillance tests but also on the real-life implementation of surveillance. Both provider and patient-related factors can lead to suboptimal adherence to surveillance recommendations. In 2015, a survey of 131 primary care providers at a large the United States urban hospital reported that 65% of the providers reported ordering annual surveillance and only 15% reported ordering biannual surveillance, many incorrectly believing that clinical examination, liver enzymes, or AFP alone without ultrasound were effective surveillance tools<sup>[29]</sup>. Another survey of 391 the United States primary care providers conducted in the same year also showed that only 45% reported ordering HCC surveillance for their patients<sup>[30]</sup>. In addition, many patients have barriers to HCC surveillance due to difficulties in scheduling, cost, and transportation<sup>[31]</sup>. Among the patients surveyed about their knowledge of HCC surveillance, a significant proportion believed that eating a healthy diet would preclude the need for HCC surveillance, or that HCC surveillance was not necessary if they had no symptoms<sup>[31]</sup>. The rates of HCC surveillance are also lower among racial/ethnic minorities and those of lower socioeconomic status<sup>[32]</sup>. A recently published systemic review and meta-analysis of 29 studies showed a pooled estimate for surveillance in 24% of patients, with striking differences in surveillance rate between patients seen in gastroenterology/hepatology clinics and patients in population-based cohorts (73.7% vs. 8.8%,  $P < 0.001$ )<sup>[33]</sup>. Compared to other etiologies of liver disease, patients with NASH or alcohol-associated cirrhosis were less likely to receive surveillance. Interventions including patient/provider education, reminder and recall

systems, and population health outreach were identified as effective strategies to improve HCC surveillance rates<sup>[33]</sup>.

Under-utilization of HCC surveillance is also a major health concern in East Asian countries despite the presence of jurisdictional surveillance programs. In 2017, a study of high-risk Chinese patients with CHB and CHC found that only 50% received routine screening for HCC, while 26.7% had incomplete or no screening. Determinants for adherence included a higher level of education, underlying liver cirrhosis, family history of HCC, better knowledge of the disease, while common barriers included lack of awareness (41.5%), absence of symptoms (38.3%), and lack of recommendation from physicians (31.9%)<sup>[34]</sup>. Another recent study of high-risk patients in Yunnan, China, found that of a total of 327 patients who were eligible for HCC surveillance, only a quarter of them underwent HCC surveillance within 7 months. High costs and perceived poor test efficacy were two major barriers, and knowledge of HCC surveillance and lifestyle also had an influence on adherence to HCC surveillance<sup>[35]</sup>. Similarly, a South Korean study also showed that the surveillance rate among high-risk patients was only 40% despite the presence of a national guideline. Only 57.1% of the patients were aware of the need for regular surveillance, and less than half (44.2%) of the patients had accurate information about the surveillance method<sup>[36]</sup>.

## POTENTIAL HARMS OF SURVEILLANCE

Clinicians must consider not only the obvious benefits of HCC surveillance, but its potential harms, which can be physical, financial, as well as psychological. A false positive or indeterminate surveillance result may cause physical harm by subjecting the patient to repeated exposure to contrast agents or ionizing radiation, or even an invasive liver biopsy. Financial harms come from the costs of screening and diagnostic evaluation, as well as transportation and days of missed work. Finally, repeatedly being reminded of one's risk of developing deadly cancer and waiting to be told the verdict every six months can be a significant emotional burden and lead to fear, anxiety, and depression. Fortunately, studies of surveillance-related harms to date have shown that the harms of HCC surveillance are mild for the vast majority of patients and that the overall benefits of HCC surveillance greatly outweigh its harms<sup>[37–39]</sup>. However, it must be noted that most of the studies focused on physical harms, and more studies are needed to properly assess the burden of financial and psychological harms from HCC surveillance.

## CURRENTLY ACCEPTED HCC SURVEILLANCE METHODS

### **Standard surveillance using ultrasound with or without alpha-fetoprotein—**

Liver ultrasonography every 6 months with or without serum AFP level is widely recommended as the standard modality for HCC surveillance [Table 2]<sup>[21–23]</sup>. The main advantages of ultrasound include its widespread availability, low cost, and noninvasiveness<sup>[40]</sup>. There have been debates surrounding the effectiveness of ultrasound-based surveillance, as the quality of liver ultrasound can be limited by various factors, including sex, body habitus, and the underlying etiology of liver disease. A study of 941 patients who received ultrasound for HCC surveillance identified male gender, body mass index, Child-Pugh class B or C cirrhosis, alcohol-related cirrhosis, NASH cirrhosis, and

inpatient status as independent risk factors for inadequate ultrasound quality<sup>[41]</sup>. A recent meta-analysis concluded that up to 21.5% of ultrasounds done for HCC surveillance were inadequate<sup>[42]</sup>. Another meta-analysis of 32 studies, including 13,367 patients, demonstrated that ultrasound had an 84% sensitivity for detection of HCC at all stages but only had a 47% sensitivity for early-stage HCC<sup>[43]</sup>. However, this study was limited by aggregating all of the studies from the pre-2000s with studies done after the 2000s, when the advent of harmonic and compound imaging significantly increased ultrasound's sensitivity for detection of early HCC<sup>[44]</sup>. Indeed, when the results were analyzed by the decade of publication, ultrasound's sensitivity for early-stage HCC increased from 29.7% in the 1990s to 62.2% in the 2010s<sup>[45]</sup>. Several recent studies reported that ultrasound with or without AFP has a sensitivity ranging between 69%–88% for early-stage HCC<sup>[46–49]</sup>.

Contrast-enhanced ultrasound (CEUS) utilizing microbubble-based contrast materials such as perflorobutane (Sonazoid) is expected to further increase the efficacy of ultrasound-based HCC surveillance. CEUS improves the assessment of tumor boundaries, tumor vascularity, and tumor characterization compared to B-mode ultrasound<sup>[50]</sup>. In a cohort of 292 patients under HCC surveillance, CEUS was able to detect 16 additional HCCs that were not detected on B-mode ultrasound<sup>[51]</sup>. In a prospective, multicenter study of 23 institutions, the average size of HCCs detected by CEUS was significantly smaller than the size of HCCs detected by B-mode ultrasound, suggesting that CEUS is superior to B-mode ultrasound for early detection<sup>[52]</sup>. Another multicenter study has reported that the use of CEUS for HCC surveillance led to a significantly reduced false positive rate by 23.2%, although it did not lead to improved early detection<sup>[53]</sup>.

Serum AFP has been widely used as a predictive biomarker for HCC and is generally associated with tumor size<sup>[54]</sup>. When used with ultrasound, it has been shown to increase the sensitivity for early-stage HCC<sup>[43]</sup>. However, AFP also has limited sensitivity and specificity for early-stage HCC. For HCC tumors less than 5cm in size, AFP has a sensitivity between 49% to 71% and specificity between 49% to 86%<sup>[55]</sup>. False elevations in AFP can be seen in the setting of active hepatic inflammation (e.g., viral hepatitis) or other liver masses such as cholangiocarcinoma<sup>[54]</sup>. Studies have proposed that the accuracy of AFP in HCC surveillance can be improved by measuring a longitudinal trend rather than a single value and also by accounting for additional factors such as serum alanine aminotransferase level and etiology of liver disease<sup>[56–58]</sup>.

**CT and MRI in HCC surveillance**—Multiphase, contrast-enhanced, cross-sectional imaging modalities such as computerized tomography (CT) or magnetic resonance imaging (MRI) are not recommended as first-line surveillance methods due to their lower availability, higher cost, exposure to radiation (CT) and contrast material (CT and MRI), and poor patient tolerance (MRI)<sup>[9]</sup>. A randomized controlled trial comparing ultrasound and CT for HCC surveillance showed that biannual ultrasonography was marginally more sensitive and less costly for detection of early-stage HCC compared to annual CT scans<sup>[59]</sup>. However, CT or MRI may be indicated as alternatives to ultrasound in patients who are likely to have inadequate ultrasound images or in certain high-risk patients in whom the benefits of contrast-enhanced cross-sectional imaging outweigh their downsides. In a prospective study at a tertiary care center, 407 patients with cirrhosis whose estimated annual risks of

HCC were greater than 5% underwent biannual HCC surveillance using paired ultrasound and liver-specific contrast-enhanced MRI. Of the 43 cases of incident HCC diagnosed over the 3 years of study period, MRI detected 37 (86.0%) while ultrasound only detected 12 (27.9%) of the cases<sup>[60]</sup>. It should be noted that this was not a randomized controlled trial and not optimally designed for a head-to-head comparison of the two modalities. In addition, a Markov model in a cohort of high-risk patients with predominantly HBV-related compensated cirrhosis showed that biannual HCC surveillance using liver-specific contrast-enhanced MRI may be more cost-effective compared to ultrasound despite its higher cost<sup>[61]</sup>. Therefore, AASLD recommends utilizing CT or MRI for HCC surveillance in select patients with inadequate ultrasound or those with a high likelihood of having an inadequate ultrasound<sup>[21]</sup>, while EASL recommends using CT or MRI for HCC surveillance in high-risk patients on the liver transplant waiting list [Table 2]<sup>[22]</sup>. To minimize the scanning time, cost, and contrast exposure during MRI, abbreviated MRI protocols have been developed with promising performances in small cohort studies<sup>[62,63]</sup>.

## EMERGING HCC SURVEILLANCE METHODS

**Novel serum protein-based biomarkers**—Given the limitations of AFP, there are ongoing efforts to search for novel blood-based biomarkers of HCC. AFP-L3 is a glycoform of AFP with a high affinity for Lens culinaris agglutinin, and it has shown promises for early detection and prediction of tumor aggressiveness in patients with HCC<sup>[64]</sup>. Des-γ-carboxy prothrombin (DCP) is a protein induced by vitamin K deficiency or antagonist-II and has been demonstrated to be a useful diagnostic and prognostic marker of HCC in several studies<sup>[65,66]</sup>. In 2014, a prospective, UK-based single-center study of 670 patients with chronic liver diseases was conducted to identify risk factors and blood-based biomarkers of HCC. The final “GALAD” score consisting of gender, age, AFP-L3, AFP, and DCP provided excellent performances with an area under the receiver operating characteristic curve (AUROC) over 0.90 for prediction of HCC regardless of stage<sup>[67]</sup>. The GALAD score was validated in a large, international cohort of nearly 7000 patients and demonstrated its abilities to discriminate patients with HCC from patients with chronic liver diseases or patients with other hepatobiliary tumors<sup>[68]</sup>. A United States study of patients with cirrhosis or chronic hepatitis B found that the GALAD score significantly outperformed liver ultrasound for detection of early-stage HCC, and that combining the GALAD score with ultrasound could achieve an AUROC of 0.98 with 95% sensitivity and 91% specificity for HCC detection<sup>[69]</sup>. A recent study of patients from Germany and Japan showed that the GALAD score might detect HCC with high accuracy in NASH patients with or without cirrhosis<sup>[70]</sup>. Despite the remarkable performances seen in recent studies, the incorporation of the GALAD model in real-life clinical practice has been slow, and it has not yet been formally endorsed by the major liver societies, and more robust phase 3 biomarker study results are eagerly awaited<sup>[71]</sup>.

**Liquid biopsy**—Liquid biopsy refers to analyzing samples of body fluids to obtain important phenotypic, genetic, and transcriptomic information about the primary tumor<sup>[72]</sup>. Recently, various liquid biopsies, including circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs), have emerged as novel biomarkers



with the potential for implementation of precision medicine in the care of patients with HCC.

CTCs are cancer cells in circulation derived from the original tumor or metastatic foci, representing a noninvasive way of sampling live tumor cells from patients with HCC<sup>[73]</sup>. Compared to other liquid biopsy approaches, CTC is less utilized as a diagnostic biomarker given its low detection rate among patients with early-stage HCC and time-consuming process for enumerating CTCs<sup>[73]</sup>. In 2017, Kalinich *et al.*<sup>[74]</sup> developed a panel of 10 HCC-specific mRNA markers and demonstrated that measuring these 10 markers in enriched CTCs enabled detecting HCC from healthy donors and chronic liver disease. Although their strategy overcame the hurdle of CTC enumeration, only 56% of all-stage HCC patients were classified correctly.

ctDNA contains DNA from dying or phagocytized tumor cells and can also provide valuable tumor-specific mutations and epigenetic changes in patients with HCC<sup>[75]</sup>. Recently, several assays measuring the methylation level of ctDNA for HCC detection have received Food and Drug Administration breakthrough device designation and Conformité Européenne Mark<sup>[76–79]</sup>. However, HCC patients in these studies were not restricted to early-stage disease, which could lead to overestimation of biomarker performance for the purpose of early HCC detection<sup>[80]</sup>.

EVs are microvesicles that transport a range of biological molecules and mediate the communication between HCC tumors and their surrounding environments<sup>[81]</sup>. Similar to ctDNA, EV and its cargoes are regarded as promising biomarkers to augment current HCC surveillance methods due to their early presence in circulation<sup>[81]</sup>. Our recent phase 2 biomarker study applied an HCC EV Digital Scoring Assay to quantify the identified 10 HCC-specific mRNA markers<sup>[74]</sup> from purified HCC EVs and showed the resultant digital scores could noninvasively detect BCLC stage 0-A HCC from cirrhosis with an AUROC of 0.93 (sensitivity = 94%, specificity = 89%)<sup>[82]</sup>. Currently, almost all of the existing EV-based biomarker studies are still at phase II (case-control)<sup>[81,83]</sup>, further phase III (prospective specimen collection, retrospective blinded evaluation), and phase IV studies (prospective cohort) are required to validate their performance for detecting early-stage HCC<sup>[80]</sup>.

**The role of artificial intelligence**—The recent decade has seen explosive growth in the application of artificial intelligence (AI) in medicine, and the field of hepatology has been no exception to this trend. AI-based machine learning algorithms, including deep learning, can process a wide spectrum of healthcare data from structured numeric data, free texts in medical documentation, high-dimensional data from multi-omics, and digitized high-resolution images from radiologic and histopathologic studies<sup>[84]</sup>. As AI algorithms have the capacity to synthesize and analyze complex relationships within large amounts of data in ways that are impossible for humans, they have great potential to improve risk prediction and diagnostic accuracy in HCC surveillance. Several recently reported machine learning models trained using clinical data from large cohorts of patients with viral hepatitis demonstrated high performances for predicting longitudinal risk of HCC incidence and significantly outperformed conventional prediction models<sup>[85–87]</sup>. Deep

learning algorithms utilizing convolutional neural networks have revolutionized computer vision and image processing, and they have been applied to ultrasound<sup>[88–90]</sup>, CT<sup>[91,92]</sup>, and MRI<sup>[93,94]</sup> images of patients with or without hepatic lesions to detect HCC, sometimes outperforming human radiologists. While there are concerns over the interpretability and universal generalizability of the AI algorithms<sup>[95]</sup>, state-of-the-art AI algorithms are rapidly being applied for the care of patients with HCC and hold great potential to fill the unmet needs in HCC surveillance.

## CONCLUSION

Surveillance in high-risk patients is critical for early detection of HCC, which leads to higher chances of curative treatment and prolonged survival. Biannual ultrasound with or without AFP remains the standard surveillance method endorsed by major societies, but contrast-enhanced cross-sectional imaging may be indicated in patients awaiting liver transplantation or patients with inadequate ultrasound image qualities. Emerging blood-based biomarkers such as the GALAD score and liquid biopsy techniques are promising additional tools for HCC detection. In addition, the rapid developments in AI technology may greatly improve individualized HCC risk prediction and interpretation of imaging studies. Finally, the significant under-utilization of HCC surveillance is a major problem. Widespread patient/provider education and outreach efforts are necessary to make sure the at-risk patients receive the benefits of HCC surveillance while minimizing the potential physical, financial, and psychological harms.

## Acknowledgments

Financial support and sponsorship

This research was funded by the American College of Gastroenterology, grant name “Junior Faculty Development Award”; United States Department of Defense, grant number CA191051; National Institutes of Health, grant number R01CA246304, R01CA253651, R01CA255727, R21CA235340, and R21CA240887.

Conflicts of interest

Dr. Tseng would like to disclose his financial interests in CytoLumina Technologies Corp. and Pulsar Therapeutics Corp. given his role as the co-founder of these companies. Dr. Yang provides a consulting service for Exact Sciences, Gilead, and Eisai. No other potential conflicts of interest relevant to this article exist. The funders had no role in the interpretation of data and in the writing of the manuscript.

## REFERENCES

1. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. *Hepatology* 2021;73 Suppl 1:4–13. DOI PubMed PMC
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018;68:394–424. DOI PubMed [PubMed: 30207593]
3. Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. *Int J Cancer* 2020;147:317–30. DOI PubMed PMC [PubMed: 31597196]
4. Chen J, Zhang Y, Lu L, Chen H, Shen A, Zhu Y. Liver cancer screening in China: practices and its extended questions. *HR* 2019:2019. DOI
5. Zheng R, Qu C, Zhang S, et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. *Chin J Cancer Res* 2018;30:571–9. DOI PubMed PMC [PubMed: 30700925]

6. Angulo P, Kleiner DE, Dam-Larsen S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. *Gastroenterology* 2015;149:389–97. DOI PubMed PMC [PubMed: 25935633]
7. Asrani SK, Mellinger J, Arab JP, Shah VH. Reducing the global burden of alcohol-associated liver disease: a blueprint for action. *Hepatology* 2021;73:2039–50. DOI PubMed [PubMed: 32986883]
8. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2021;7:6. DOI PubMed [PubMed: 33479224]
9. Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. *BMJ* 2020;371:m3544. DOI PubMed
10. Cillo U, Vitale A, Grigoletto F, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. *J Hepatol* 2006;44:723–31. DOI PubMed [PubMed: 16488051]
11. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018;391:1301–14. DOI PubMed [PubMed: 29307467]
12. Finn RS, Zhu AX, Farah W, et al. Therapies for advanced stage hepatocellular carcinoma with macrovascular invasion or metastatic disease: a systematic review and meta-analysis. *Hepatology* 2018;67:422–35. DOI PubMed [PubMed: 28881497]
13. Chen JG, Parkin DM, Chen QG, et al. Screening for liver cancer: results of a randomised controlled trial in Qidong, China. *J Med Screen* 2003;10:204–9. DOI PubMed [PubMed: 14738659]
14. Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. *J Cancer Res Clin Oncol* 2004;130:417–22. DOI PubMed [PubMed: 15042359]
15. Poustchi H, Farrell GC, Strasser SI, Lee AU, McCaughan GW, George J. Feasibility of conducting a randomized control trial for liver cancer screening: is a randomized controlled trial for liver cancer screening feasible or still needed? *Hepatology* 2011;54:1998–2004. DOI PubMed [PubMed: 21800340]
16. Naimark D, Naglie G, Detsky AS. The meaning of life expectancy: what is a clinically significant gain? *J Gen Intern Med* 1994;9:702–7. DOI PubMed [PubMed: 7876956]
17. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? *CMAJ* 1992;146:473–81. PubMed PMC [PubMed: 1306034]
18. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. *PLoS Med* 2014;11:e1001624. DOI PubMed PMC
19. Lin OS, Keeffe EB, Sanders GD, Owens DK. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. *Aliment Pharmacol Ther* 2004;19:1159–72. DOI PubMed [PubMed: 15153169]
20. Yang JD, Mannalithara A, Piscitello AJ, et al. Impact of surveillance for hepatocellular carcinoma on survival in patients with compensated cirrhosis. *Hepatology* 2018;68:78–88. DOI PubMed PMC [PubMed: 29023828]
21. Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology* 2018;68:723–50. DOI PubMed [PubMed: 29624699]
22. Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. *J Hepatol* 2018;69:182–236. DOI [PubMed: 29628281]
23. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. *Hepatol Int* 2017;11:317–70. DOI PubMed PMC [PubMed: 28620797]
24. Bréchet C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. *Gastroenterology* 2004;127:S56–61. DOI PubMed [PubMed: 15508104]
25. Papatheodoridis G, Dalekos G, Sypsa V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. *J Hepatol* 2016;64:800–6. DOI PubMed [PubMed: 26678008]
26. Yang M, Parikh ND, Liu H, et al. Incidence and risk factors of hepatocellular carcinoma in patients with hepatitis C in China and the United States. *Sci Rep* 2020;10:20922. DOI PubMed PMC

27. Xie DY, Ren ZG, Zhou J, Fan J, Gao Q. 2019 Chinese clinical guidelines for the management of hepatocellular carcinoma: updates and insights. *Hepatobiliary Surg Nutr* 2020;9:452–63. DOI PubMed PMC [PubMed: 32832496]
28. Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. *Gastroenterology* 2020;158:1822–30. DOI PubMed PMC [PubMed: 32006545]
29. Dalton-Fitzgerald E, Tiro J, Kandunoori P, Halm EA, Yopp A, Singal AG. Practice patterns and attitudes of primary care providers and barriers to surveillance of hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2015;13:791–8.e1. DOI PubMed PMC [PubMed: 25019694]
30. McGowan CE, Edwards TP, Luong MU, Hayashi PH. Suboptimal surveillance for and knowledge of hepatocellular carcinoma among primary care providers. *Clin Gastroenterol Hepatol* 2015;13:799–804. DOI PubMed PMC [PubMed: 25117773]
31. Farvardin S, Patel J, Khambaty M, et al. Patient-reported barriers are associated with lower hepatocellular carcinoma surveillance rates in patients with cirrhosis. *Hepatology* 2017;65:875–84. DOI PubMed PMC [PubMed: 27531684]
32. Singal AG, Li X, Tiro J, et al. Racial, social, and clinical determinants of hepatocellular carcinoma surveillance. *Am J Med* 2015;128:90.e1–7. DOI PubMed PMC
33. Wolf E, Rich NE, Marrero JA, Parikh ND, Singal AG. Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis. *Hepatology* 2021;73:713–25. DOI PubMed PMC [PubMed: 32383272]
34. Xu K, Watanabe-Galloway S, Rochling FA, et al. Practice, knowledge, and barriers for screening of hepatocellular carcinoma among high-risk Chinese patients. *Ann Glob Health* 2017;83:281–92. DOI PubMed [PubMed: 28619403]
35. Dai J, Zhao J, Du Y, Zhuang L, McNeil EB, Chongsuvivatwong V. Adherence to hepatocellular carcinoma surveillance and perceived barriers among high-risk chronic liver disease patients in Yunnan, China. *Cancer Manag Res* 2020;12:6209–20. DOI PubMed PMC [PubMed: 32884337]
36. Im S, Jang ES, Lee JH, et al. Surveillance rate and its impact on survival of hepatocellular carcinoma patients in South Korea: a cohort study. *Cancer Res Treat* 2019;51:1357–69. DOI PubMed PMC [PubMed: 30744319]
37. Atiq O, Tiro J, Yopp AC, et al. An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis. *Hepatology* 2017;65:1196–205. DOI PubMed PMC [PubMed: 27775821]
38. Konerman MA, Verma A, Zhao B, Singal AG, Lok AS, Parikh ND. Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program. *Liver Transpl* 2019;25:369–79. DOI PubMed PMC [PubMed: 30582779]
39. Singal AG, Patibandla S, Obi J, et al. Benefits and harms of hepatocellular carcinoma surveillance in a prospective cohort of patients with cirrhosis. *Clin Gastroenterol Hepatol* 2021;19:1925–32.e1. DOI PubMed PMC [PubMed: 32920214]
40. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. *World J Gastroenterol* 2019;25:1550–9. DOI PubMed PMC [PubMed: 30983815]
41. Simmons O, Fetzer DT, Yokoo T, et al. Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis. *Aliment Pharmacol Ther* 2017;45:169–77. DOI PubMed PMC [PubMed: 27862091]
42. Hong SB, Kim DH, Choi SH, et al. Inadequate ultrasound examination in hepatocellular carcinoma surveillance: a systematic review and meta-analysis. *J Clin Med* 2021;10:3535. DOI PubMed PMC [PubMed: 34441831]
43. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. *Gastroenterology* 2018;154:1706–18.e1. DOI PubMed PMC [PubMed: 29425931]
44. Sammon J, Khalili K. Hepatocellular carcinoma surveillance: the often-neglected practice. *Hepatobiliary Surg Nutr* 2019;9:77–9. DOI PubMed PMC

45. Khalili K. Historical data are not relevant to the diagnostic performance of ultrasound in surveillance for hepatocellular carcinoma. *Gastroenterology* 2019;157:899–900. DOI PubMed [PubMed: 31108052]
46. Khalili K, Menezes R, Kim TK, et al. The effectiveness of ultrasound surveillance for hepatocellular carcinoma in a Canadian centre and determinants of its success. *Can J Gastroenterol Hepatol* 2015;29:267–73. DOI PubMed PMC [PubMed: 26076226]
47. Kuo YH, Lu SN, Chen CL, et al. Hepatocellular carcinoma surveillance and appropriate treatment options improve survival for patients with liver cirrhosis. *Eur J Cancer* 2010;46:744–51. DOI PubMed [PubMed: 20060710]
48. Noda I, Kitamoto M, Nakahara H, et al. Regular surveillance by imaging for early detection and better prognosis of hepatocellular carcinoma in patients infected with hepatitis C virus. *J Gastroenterol* 2010;45:105–12. DOI PubMed [PubMed: 19866332]
49. Santi V, Trevisani F, Gramenzi A, et al. ; Italian Liver Cancer (ITA. LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. *J Hepatol* 2010;53:291–7. DOI PubMed [PubMed: 20483497]
50. Maruyama H, Sekimoto T, Yokosuka O. Role of contrast-enhanced ultrasonography with Sonazoid for hepatocellular carcinoma: evidence from a 10-year experience. *J Gastroenterol* 2016;51:421–33. DOI PubMed [PubMed: 26694825]
51. Kudo M, Hatanaka K, Kumada T, Toyoda H, Tada T. Double-contrast ultrasound: a novel surveillance tool for hepatocellular carcinoma. *Am J Gastroenterol* 2011;106:368–70. DOI PubMed [PubMed: 21301463]
52. Kudo M, Ueshima K, Osaki Y, et al. B-mode ultrasonography versus contrast-enhanced ultrasonography for surveillance of hepatocellular carcinoma: a prospective multicenter randomized controlled trial. *Liver Cancer* 2019;8:271–80. DOI PubMed PMC [PubMed: 31602370]
53. Park JH, Park MS, Lee SJ, et al. Contrast-enhanced US with perfluorobutane for hepatocellular carcinoma surveillance: a multicenter diagnostic trial (SCAN). *Radiology* 2019;292:638–46. DOI PubMed [PubMed: 31287387]
54. Ahmed Mohammed HF, Roberts LR. Should AFP (or any biomarkers) be used for HCC surveillance? *Curr Hepatol Rep* 2017;16:137–45. DOI PubMed PMC [PubMed: 29085770]
55. Song PP, Xia JF, Inagaki Y, et al. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma. *World J Gastroenterol* 2016;22:262–74. DOI PubMed PMC [PubMed: 26755875]
56. Lee E, Edward S, Singal AG, Lavieri MS, Volk M. Improving screening for hepatocellular carcinoma by incorporating data on levels of  $\alpha$ -fetoprotein, over time. *Clin Gastroenterol Hepatol* 2013;11:437–40. DOI PubMed [PubMed: 23247324]
57. Gopal P, Yopp AC, Waljee AK, et al. Factors that affect accuracy of  $\alpha$ -fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. *Clin Gastroenterol Hepatol* 2014;12:870–7. DOI PubMed PMC [PubMed: 24095974]
58. Yang JD, Dai J, Singal AG, et al. Improved performance of serum alpha-fetoprotein for hepatocellular carcinoma diagnosis in HCV cirrhosis with normal alanine transaminase. *Cancer Epidemiol Biomarkers Prev* 2017;26:1085–92. DOI PubMed PMC [PubMed: 28258053]
59. Pocha C, Dieperink E, McMaken KA, Knott A, Thuras P, Ho SB. Surveillance for hepatocellular cancer with ultrasonography vs. computed tomography -- a randomised study. *Aliment Pharmacol Ther* 2013;38:303–12. DOI PubMed [PubMed: 23750991]
60. Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. *JAMA Oncol* 2017;3:456–63. DOI PubMed PMC [PubMed: 27657493]
61. Kim HL, An J, Park JA, Park SH, Lim YS, Lee EK. Magnetic resonance imaging is cost-effective for hepatocellular carcinoma surveillance in high-risk patients with cirrhosis. *Hepatology* 2019;69:1599–613. DOI PubMed [PubMed: 30365164]
62. Besa C, Lewis S, Pandharipande PV, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-

- weighted imaging at the delayed phase post gadoxetic acid. *Abdom Radiol (NY)* 2017;42:179–90. DOI PubMed [PubMed: 27448609]
63. Marks RM, Ryan A, Heba ER, et al. Diagnostic per-patient accuracy of an abbreviated hepatobiliary phase gadoxetic acid-enhanced MRI for hepatocellular carcinoma surveillance. *AJR Am J Roentgenol* 2015;204:527–35. DOI PubMed [PubMed: 25714281]
  64. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. *Clinica Chimica Acta* 2001;313:15–9. DOI PubMed
  65. Marrero JA, Su GL, Wei W, et al. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients. *Hepatology* 2003;37:1114–21. DOI PubMed [PubMed: 12717392]
  66. Park H, Kim SU, Park JY, et al. Clinical usefulness of double biomarkers AFP and PIVKA-II for subdividing prognostic groups in locally advanced hepatocellular carcinoma. *Liver Int* 2014;34:313–21. DOI PubMed [PubMed: 23895043]
  67. Johnson PJ, Pirrie SJ, Cox TF, et al. The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers. *Cancer Epidemiol Biomarkers Prev* 2014;23:144–53. DOI PubMed [PubMed: 24220911]
  68. Berhane S, Toyoda H, Tada T, et al. Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. *Clin Gastroenterol Hepatol* 2016;14:875–886.e6. DOI PubMed [PubMed: 26775025]
  69. Yang JD, Addissie BD, Mara KC, et al. GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score. *Cancer Epidemiol Biomarkers Prev* 2019;28:531–8. DOI PubMed PMC [PubMed: 30464023]
  70. Best J, Bechmann LP, Sowa JP, et al. GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis. *Clin Gastroenterol Hepatol* 2020;18:728–35.e4. DOI PubMed [PubMed: 31712073]
  71. Roberts LR. Current status of the GALAD and BALAD biomarker models for hepatocellular carcinoma. *Gastroenterol Hepatol (N Y)* 2019;15:672–5. PubMed PMC [PubMed: 31892914]
  72. Ye Q, Ling S, Zheng S, Xu X. Liquid biopsy in hepatocellular carcinoma: circulating tumor cells and circulating tumor DNA. *Mol Cancer* 2019;18:114. DOI PubMed PMC [PubMed: 31269959]
  73. Ahn JC, Teng PC, Chen PJ, et al. Detection of circulating tumor cells and their implications as a biomarker for diagnosis, prognostication, and therapeutic monitoring in hepatocellular carcinoma. *Hepatology* 2021;73:422–36. DOI PubMed PMC [PubMed: 32017145]
  74. Kalinich M, Bhan I, Kwan TT, et al. An RNA-based signature enables high specificity detection of circulating tumor cells in hepatocellular carcinoma. *Proc Natl Acad Sci U S A* 2017;114:1123–8. DOI PubMed PMC [PubMed: 28096363]
  75. Yang JD, Liu MC, Kisiel JB. Circulating Tumor DNA and hepatocellular carcinoma. *Semin Liver Dis* 2019;39:452–62. DOI PubMed [PubMed: 31226727]
  76. Oussalah A, Rischer S, Bensenane M, et al. Plasma mSEPT9: a novel circulating cell-free DNA-based epigenetic biomarker to diagnose hepatocellular carcinoma. *EBioMedicine* 2018;30:138–47. DOI PubMed PMC [PubMed: 29627389]
  77. Chalasani NP, Ramasubramanian TS, Bhattacharya A, et al. A novel blood-based panel of methylated DNA and Protein markers for detection of early-stage hepatocellular carcinoma. *Clin Gastroenterol Hepatol* 2021;19:2597–2605.e4. DOI PubMed [PubMed: 32889146]
  78. Xu RH, Wei W, Krawczyk M, et al. Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma. *Nat Mater* 2017;16:1155–61. DOI PubMed [PubMed: 29035356]
  79. Tran NH, Kisiel J, Roberts LR. Using cell-free DNA for HCC surveillance and prognosis. *JHEP Rep* 2021;3:100304. DOI PubMed PMC
  80. Singal AG, Hoshida Y, Pinato DJ, et al. International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma. *Gastroenterology* 2021;160:2572–84. DOI PubMed PMC [PubMed: 33705745]
  81. Lee YT, Tran BV, Wang JJ, et al. The role of extracellular vesicles in disease progression and detection of hepatocellular carcinoma. *Cancers (Basel)* 2021;13:3076. DOI PubMed PMC [PubMed: 34203086]

82. Sun N, Lee YT, Zhang RY, et al. Purification of HCC-specific extracellular vesicles on nanosubstrates for early HCC detection by digital scoring. *Nat Commun* 2020;11:4489. DOI PubMed PMC [PubMed: 32895384]
83. von Felden J, Garcia-Lezana T, Dogra N, et al. Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer. *Gut* 2021. DOI PubMed PMC
84. Ahn JC, Connell A, Simonetto DA, Hughes C, Shah VH. Application of artificial intelligence for the diagnosis and treatment of liver diseases. *Hepatology* 2021;73:2546–63. DOI PubMed [PubMed: 33098140]
85. Ioannou GN, Tang W, Beste LA, et al. Assessment of a deep learning model to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis. *JAMA Netw Open* 2020;3:e2015626. DOI PubMed PMC
86. Phan DV, Chan CL, Li AA, Chien TY, Nguyen VC. Liver cancer prediction in a viral hepatitis cohort: a deep learning approach. *Int J Cancer* 2020;147:2871–8. DOI PubMed [PubMed: 32761609]
87. Nam JY, Sinn DH, Bae J, Jang ES, Kim JW, Jeong SH. Deep learning model for prediction of hepatocellular carcinoma in patients with HBV-related cirrhosis on antiviral therapy. *JHEP Rep* 2020;2:100175. DOI PubMed PMC
88. Schmauch B, Herent P, Jehanno P, et al. Diagnosis of focal liver lesions from ultrasound using deep learning. *Diagn Interv Imaging* 2019;100:227–33. DOI PubMed [PubMed: 30926443]
89. Brehar R, Mitrea DA, Vancea F, et al. Comparison of deep-learning and conventional machine-learning methods for the automatic recognition of the hepatocellular carcinoma areas from ultrasound images. *Sensors (Basel)* 2020;20:3085. DOI PubMed PMC
90. Jin J, Yao Z, Zhang T, et al. Deep learning radiomics model accurately predicts hepatocellular carcinoma occurrence in chronic hepatitis B patients: a five-year follow-up. *Am J Cancer Res* 2021;11:576–89. PubMed PMC [PubMed: 33575088]
91. Yasaka K, Akai H, Abe O, Kiryu S. Deep learning with convolutional neural network for differentiation of liver masses at dynamic contrast-enhanced CT: a preliminary study. *Radiology* 2018;286:887–96. DOI PubMed [PubMed: 29059036]
92. Shi W, Kuang S, Cao S, et al. Deep learning assisted differentiation of hepatocellular carcinoma from focal liver lesions: choice of four-phase and three-phase CT imaging protocol. *Abdom Radiol (NY)* 2020;45:2688–97. DOI PubMed [PubMed: 32232524]
93. Hamm CA, Wang CJ, Savic LJ, et al. Deep learning for liver tumor diagnosis part I: development of a convolutional neural network classifier for multi-phasic MRI. *Eur Radiol* 2019;29:3338–47. DOI PubMed PMC [PubMed: 31016442]
94. Wang CJ, Hamm CA, Savic LJ, et al. Deep learning for liver tumor diagnosis part II: convolutional neural network interpretation using radiologic imaging features. *Eur Radiol* 2019;29:3348–57. DOI PubMed PMC [PubMed: 31093705]
95. Azuaje F. Artificial intelligence for precision oncology: beyond patient stratification. *NPJ Precis Oncol* 2019;3:6. DOI PubMed PMC [PubMed: 30820462]

**Table 1.**

## Indications for HCC surveillance

AASLD	EASL	APASL
1. All adults with cirrhosis, except for Child-Pugh class C patients ineligible for liver transplant	1. Cirrhotic patients, Child-Pugh stage A & B	1. All adults with cirrhosis, except for Child-Pugh class C patients ineligible for liver transplant
2. High risk patients with HBV - Asian men age > 40 - Asian women age > 50 - African ancestry - Family history of HCC	2. Cirrhotic patients, Child-Pugh stage C awaiting LT 3. Non-cirrhotic HBV patients at intermediate or high risk of HCC according to PAGE-B* classes for Caucasians 4. Non-cirrhotic F3 patients based on individual risk assessment	2. High risk patients with HBV - Asian men age > 40 - Asian women age > 50 - African ancestry age > 20 - Family history of HCC
<b>AGA:</b> In addition to above recommendations, patients with non-alcoholic fatty liver disease with noninvasive markers showing evidence of advanced liver fibrosis or cirrhosis should be considered for HCC screening		
<b>Chinese clinical guidelines:</b> All patients with cirrhosis, HBV, and HCV		

A total sum of 10 or more indicates intermediate or high risk of hepatocellular carcinoma.

\* PAGE-B (platelet, age, gender, hepatitis B) score is calculated using age (16–29 = 0, 30–39 = 2, 40–49 = 4, 50–59 = 6, 60–69 = 8, 70 = 10), sex (male = 6, female = 0), and platelet count ( > 200,000/ $\mu$ L = 0, 100,000–199,999/ $\mu$ L = 1, < 100,000/ $\mu$ L = 2). AASLD: American Association for the Study of the Liver Diseases; APASL: Asian Pacific Association for the Study of the Liver; EASL: European Association for the Study of the Liver; HBV: hepatitis B virus; HCC: hepatocellular carcinoma.



**Table 2.**

**Recommended HCC surveillance methods**

AASLD	EASL	APASL
1. Biannual abdominal ultrasonography with or without AFP 2. CT and MRI may be utilized in select patients with a high likelihood of having an inadequate ultrasound or if ultrasound is attempted but inadequate	1. Biannual abdominal ultrasonography 2. AFP not recommended particularly in patients with active liver inflammation 3. MRI/CT can be used for patients on the waiting list for liver transplant 4. MRI/CT can be used for patients who have had inadequate ultrasonography, but their risk and cost make their use in long-term surveillance highly debatable	1. Biannual abdominal ultrasonography with or without AFP 2. Cutoff value of AFP should be set at 200ng/mL when used in combination with ultrasonography 3. Cutoff value of AFP can be set lower with hepatitis virus suppression or eradication

**Chinese clinical guidelines: Biannual abdominal ultrasonography with AFP**

AASLD: American Association for the Study of the Liver Diseases; AFP: alpha-fetoprotein; APASL: Asian Pacific Association for the Study of the Liver; CT: computerized tomography; EASL: European Association for the Study of the Liver; HCC: hepatocellular carcinoma; MRI: magnetic resonance imaging.